Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202 ...
ROCKVILLE, Md., Nov. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE ®, the multi-center, open-label trial of RGX-202, a potential best-in-class gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback